In the last trading session, 10.9 million shares of the Citius Pharmaceuticals Inc (NASDAQ:CTXR) were traded, and its beta was 1.65. Most recently the company’s share price was $0.20, and it changed around -$0.13 or -39.10% from the last close, which brings the market valuation of the company to $22.02M. CTXR currently trades at a discount to its 52-week high of $1.07, offering almost -435.0% off that amount. The share price’s 52-week low was $0.25, which indicates that the current value has fallen by an impressive -25.0% since then. We note from Citius Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 3.33 million shares, with the 3-month average coming to 1.15 million.
Citius Pharmaceuticals Inc stock received a consensus recommendation rating of Overweight, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 3 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended CTXR as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Citius Pharmaceuticals Inc is expected to report earnings per share of -0.04 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Citius Pharmaceuticals Inc (NASDAQ:CTXR) trade information
Instantly CTXR has showed a red trend with a performance of -39.10% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.5135 on recent trading dayincreased the stock’s daily price by 61.05%. The company’s shares are currently down -73.56% year-to-date, but still down -51.40% over the last five days. On the other hand, Citius Pharmaceuticals Inc (NASDAQ:CTXR) is -51.22% down in the 30-day period. We can see from the shorts that 11.79 million shares have been sold at a short interest cover period of 13.22 day(s).
Citius Pharmaceuticals Inc (CTXR) estimates and forecasts
Citius Pharmaceuticals Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -69.15 percent over the past six months and at a -8.33% annual growth rate that is well below the industry average of 15.60%.
2 analysts expect Citius Pharmaceuticals Inc to make 10.59M in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at ∞%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 28.21%.
CTXR Dividends
Citius Pharmaceuticals Inc’s next quarterly earnings report is expected to be released in December.
Citius Pharmaceuticals Inc (NASDAQ:CTXR)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 6.81% of Citius Pharmaceuticals Inc shares, and 13.05% of them are in the hands of institutional investors. The stock currently has a share float of 14.00%. Citius Pharmaceuticals Inc stock is held by 65.0 institutions, with ARMISTICE CAPITAL, LLC being the largest institutional investor. By 2024-06-30, it held 6.3845% of the shares, which is about 10.16 million shares worth $5.93 million.
VANGUARD GROUP INC, with 3.9776% or 6.33 million shares worth $3.69 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
